Herald Van Der Lindeof HSBC believes that earnings growth will remain strong, making Indian equities an attractive investment option. Unlike other markets in the region, India s macro story is resilient and supported by factors such as good export numbers, domestic investments, and a growing consumer base. Van Der Linde recommends investing in banks, consumer staples, and retailers. While there may be a tactical shift from small and midcaps to largecaps, he sees potential in domestic-oriented companies.
Hemang Jani suggests moving allocation from midcap/smallcap companies to largecaps like Lemon Tree and Indian Hotels, as well as pharma and NBFCs. Reliance is expected to perform well due to Jio s growth and positive valuation. Moving 10-15% portfolio to largecaps is sensible. The NBFC sector is stabilizing, with Poonawalla Fincorp and LIC Housing expected to deliver strong results. Midcaps are still a good investment, but selective choices are important. The pharma sector has rebounded, with Cipla, Sun Pharma, Dr Reddy s, Laurus Labs, and Aurobindo Pharma as top bets.
Sunil Subramaniam says: “Multi-asset funds are now the only way to buy paper gold in a tax evasion manner. What our fund proposes to do is for a moderate investor who wants long-term inflation and fixed deposit beating returns with lower volatility, a blending of gold and equity in the same portfolio achieves a sharp reduction in risk but with not a commensuration return in rewards.”